Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America
Propanc Biopharma (OTC Pink: PPCB) has received a Notice of Allowance for its 'Proenzyme Composition' patent from the Canadian Intellectual Property Office. This patent broadly covers high dose and high ratio claims for future clinical doses of PRP, the company's lead asset for treating recurring and metastatic cancer. It's the second Canadian patent allowed or granted, part of Propanc's 93-patent portfolio filed in major jurisdictions. The patent is important for future clinical dosage ranges as Propanc advances towards a Phase 1 First-In-Human study in advanced cancer patients with solid tumors. PRP targets the global metastatic cancer treatment market, projected to reach $111.2 Billion by 2027. The patent has been granted in Europe, Japan, and South East Asia, and is under examination in the US.
Propanc Biopharma (OTC Pink: PPCB) ha ricevuto un Avviso di Concessione per il suo brevetto sulla 'Composizione di Proenzimi' dall'Ufficio della Proprietà Intellettuale Canadese. Questo brevetto copre ampiamente le richieste di dosi elevate e ad alto rapporto per le future dosi cliniche di PRP, il principale asset dell'azienda per il trattamento di cancro ricorrente e metastatici. Si tratta del secondo brevetto canadese concesso o autorizzato, parte del portafoglio di 93 brevetti di Propanc depositati in giurisdizioni principali. Il brevetto è importante per i futuri intervalli di dosaggio clinico mentre Propanc si sta avvicinando a uno studio di Fase 1 First-In-Human su pazienti affetti da cancro avanzato con tumori solidi. PRP si rivolge al mercato globale del trattamento del cancro metastatico, previsto per raggiungere 111,2 miliardi di dollari entro il 2027. Il brevetto è stato concesso in Europa, Giappone e Sud-est asiatico, ed è attualmente in fase di esame negli Stati Uniti.
Propanc Biopharma (OTC Pink: PPCB) ha recibido un Aviso de Concesión para su patente sobre 'Composición de Proenzimas' de la Oficina de Propiedad Intelectual de Canadá. Esta patente cubre ampliamente las reivindicaciones de alta dosis y alta proporción para futuras dosis clínicas de PRP, el principal activo de la compañía para tratar el cáncer recurrente y metastásico. Es la segunda patente canadiense concedida o autorizada, parte del portafolio de 93 patentes de Propanc presentado en jurisdicciones importantes. La patente es importante para los futuros rangos de dosificación clínica mientras Propanc avanza hacia un estudio de Fase 1 First-In-Human en pacientes con cáncer avanzado con tumores sólidos. PRP está dirigido al mercado global de tratamiento del cáncer metastásico, que se prevé alcanzará 111,2 mil millones de dólares para 2027. La patente ha sido concedida en Europa, Japón y el sureste asiático, y está bajo examen en EE. UU.
Propanc Biopharma (OTC Pink: PPCB)는 캐나다 지식 재산청으로부터 ‘프로효소 조성물’ 특허에 대한 허가 통지서를 받았습니다. 이 특허는 PRP의 미래 임상 용량에 대한 고용량 및 고비율 청구를 광범위하게 다룹니다. PRP는 재발성 및 전이성 암 치료를 위한 회사의 주요 자산입니다. 이는 두 번째 캐나다 특허이며, 주요 관할권에 제출된 Propanc의 93개 특허 포트폴리오의 일부입니다. 이 특허는 Propanc이 고형 종양을 가진 진행성 암 환자를 대상으로 1상 인체 첫 임상 시험을 진행하는 데 중요한 미래 임상 용량 범위에 해당합니다. PRP는 2027년까지 1,112억 달러에 이를 것으로 예상되는 전 세계 전이성 암 치료 시장을 목표로 합니다. 이 특허는 유럽, 일본 및 동남아시아에 부여되었으며, 미국에서도 심사 중입니다.
Propanc Biopharma (OTC Pink: PPCB) a reçu un Avis d'Accord pour son brevet de 'Composition de Proenzymes' de l'Office canadien de la propriété intellectuelle. Ce brevet couvre largement les revendications de haute dose et de haut ratio pour les futures doses cliniques de PRP, l'actif principal de l'entreprise pour le traitement du cancer récurrent et métastatique. Il s'agit du deuxième brevet canadien accordé ou autorisé, faisant partie du portefeuille de 93 brevets de Propanc déposés dans des juridictions majeures. Le brevet est important pour les futures plages de dosage clinique alors que Propanc avance vers une étude de Phase 1 First-In-Human chez des patients atteints de cancer avancé avec des tumeurs solides. PRP cible le marché mondial du traitement des cancers métastatiques, qui devrait atteindre 111,2 milliards de dollars d'ici 2027. Le brevet a été accordé en Europe, au Japon et en Asie du Sud-Est, et est en cours d'examen aux États-Unis.
Propanc Biopharma (OTC Pink: PPCB) hat eine Erlaubnismitteilung für sein ‘Proenzymzusammensetzung’-Patent vom kanadischen Amt für geistiges Eigentum erhalten. Dieses Patent deckt umfassend Ansprüche auf hohe Dosen und hohe Verhältnisse für zukünftige klinische Dosen von PRP ab, dem Hauptvermögen des Unternehmens zur Behandlung von wiederkehrendem und metastaschem Krebs. Es ist das zweite kanadische Patent, das genehmigt oder erteilt wurde, und Teil des Portfolio von 93 Patenten von Propanc, das in wichtigen Gerichtsbarkeiten eingereicht wurde. Das Patent ist wichtig für künftige klinische Dosierungsbereiche, da Propanc auf eine Phase 1 First-In-Human-Studie bei fortgeschrittenen Krebspatienten mit soliden Tumoren hinarbeitet. PRP zielt auf den globalen Markt für die Behandlung von metastaschem Krebs ab, der bis 2027 voraussichtlich 111,2 Milliarden US-Dollar erreichen wird. Das Patent wurde in Europa, Japan und Südostasien erteilt und wird derzeit in den USA geprüft.
- Received Notice of Allowance for 'Proenzyme Composition' patent in Canada
- Patent covers high dose and high ratio claims for future clinical doses of PRP
- Second Canadian patent allowed or granted
- Total of 93 patents filed in major jurisdictions
- Patent granted in Europe, Japan, and South East Asia
- Targeting global metastatic cancer treatment market projected at $111.2 Billion by 2027
- Patent still under examination in the United States
Patent Broadly Captures Both High Dose & High Ratio Claims for Future Clinical Doses of PRP Allowed by the Canadian Intellectual Property Office
The proenzymes composition patent is an important part of the IP portfolio covering possible future clinical dosage ranges for PRP, as the Company advances to a Phase 1, First-In-Human (FIH) study in advanced cancer patients suffering from solid tumors. The patent has been granted in major jurisdictions such as
“We continue to grow our intellectual property portfolio in key global jurisdictions,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “Our lead asset, PRP, is a novel method to prevent and treat metastatic cancer from solid tumors, but without the severe, or even serious side effects normally associated with standard therapies. The proenzymes composition patent will cover future PRP clinical doses as a welcome addition to the treatment process, such as when resistant tumors could be pretreated by PRP, as a chemo-sensitizing agent. This practical application of our patent portfolio provides a strong indication of our commercial embodiment for future licensing partners, which we believe can potentially revolutionize the way we treat metastatic cancer from solid tumors. Today, metastatic cancer remains the main cause of patient death for sufferers. We look forward to updating our shareholders as we progress.”
About PRP:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include pancreatic, ovarian, kidney, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers. Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.
To view the Company’s “Mechanism of Action” video on the Company’s lead asset, PRP, please click on the following link: http://www.propanc.com/news-media/video.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the planned studies and market projections described above and the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements because of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary business partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240814093299/en/
Investor Relations and Media Contacts:
James Nathanielsz
Propanc Biopharma, Inc.
irteam@propanc.com
+61-3-9882-0780
Source: Propanc Biopharma, Inc.
FAQ
What patent did Propanc Biopharma (PPCB) receive a Notice of Allowance for in Canada?
What does the new patent cover for Propanc Biopharma's (PPCB) PRP?
How many patents does Propanc Biopharma (PPCB) have in its portfolio?
What is the projected value of the global metastatic cancer treatment market that Propanc Biopharma (PPCB) is targeting?
